Value of Stool-Based Colorectal Cancer Screening: Integrating Real-World Adherence, Detection, and Prevention in a Cohort-Based Modeling Analysis
Journal of Clinical Medicine · 20.12.2025 · 15 (1) · 41
DOI: 10.3390/jcm15010041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 20.12.2025. Verfasst von A Mark Fendrick und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Exact Sciences Corporation.
Abstract (Originalsprache)
Background/Objectives: Modeling analyses for colorectal cancer (CRC) screening focusing solely on the costs of screening do not fully capture the value of screening programs. We evaluated the clinical and economic effects of CRC stool-based screening tests, including impacts on cancer-related outcomes.
Methods
A cohort-based decision-analytic cost-estimator model estimated outcomes for a single round of screening with next-generation multi-target stool DNA (ng mt-sDNA) test or fecal immunochemical test (FIT) from a US payer perspective. Undiagnosed cancers were assumed to become symptomatic (and detected) within 10 years. Clinical assumptions, advanced precancerous lesion and CRC prevalence, and test performance inputs were from clinical trial data. Adherence rates for initial screening and follow-up colonoscopy after a positive result were from real-world data. Input costs included the screening tests, follow-up colonoscopy (with and without polypectomy), and CRC treatment.
Results
Compared with FIT, more individuals completed ng mt-sDNA (321,000 vs. 713,000, respectively), leading to the detection of more CRC cases (436 with FIT vs. 2235 with ng mt-sDNA), more advanced precancerous lesions, and more CRC at earlier stages. The cost of screening per patient screened was USD 801 for ng mt-sDNA and USD 124 for FIT. Follow-up colonoscopy cost was USD 149 million with ng mt-sDNA versus USD 22 million with FIT, whereas CRC treatment costs were lower for ng mt-sDNA (USD 1423 million versus USD 1474 million, respectively). When accounting for both direct and CRC averted costs, the total cost of screening and treatment was USD 1383 million with ng mt-sDNA versus USD 1427 million with FIT.
Conclusions
Higher screening costs with ng mt-sDNA versus FIT are counterbalanced by savings realized from enhanced CRC prevention and earlier detection due to the superior test performance and better adherence with ng mt-sDNA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55902, USA.
- Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
- Exact Sciences Corporation, Madison, WI 53719, USA.
- Department of Mechanical and Industrial Engineering, Northeastern University, Boston, MA 02115, USA.
ORCID-Profile: A Mark Fendrick, Derek W Ebner, Chris Estes, Mohammad Dehghani
Förderung
- Exact Sciences Corporation
Zitieren
APA
Fendrick, A. M., Ebner, D. W., Dore, M., Estes, C., Aranda, G., & Dehghani, M. (2025). Value of Stool-Based Colorectal Cancer Screening: Integrating Real-World Adherence, Detection, and Prevention in a Cohort-Based Modeling Analysis. Journal of Clinical Medicine, 15(1), 41. https://doi.org/10.3390/jcm15010041
Vancouver
Fendrick AM, Ebner DW, Dore M, Estes C, Aranda G, Dehghani M. Value of Stool-Based Colorectal Cancer Screening: Integrating Real-World Adherence, Detection, and Prevention in a Cohort-Based Modeling Analysis. Journal of Clinical Medicine. 2025;15(1):41. doi:10.3390/jcm15010041
BibTeX
@article{Fendrick2025,
author = {Fendrick, A Mark and Ebner, Derek W and Dore, Michael and Estes, Chris and Aranda, Gustavus and Dehghani, Mohammad},
title = {Value of Stool-Based Colorectal Cancer Screening: Integrating Real-World Adherence, Detection, and Prevention in a Cohort-Based Modeling Analysis},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {15},
number = {1},
pages = {41},
doi = {10.3390/jcm15010041}
}
EUVIMED